Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
Glucagon-like peptide 1 (GLP-1) receptor agonists have acquired importance in Type 2 diabetes (T2D) treatment due to their glycemic advantages, cardiorenal effects, and favorable body weight. Despite this, the continuous discovery of higher effectiveness treatments is critical to addressing ongoing...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Health Sciences Review |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772632022000216 |
| _version_ | 1818049522677317632 |
|---|---|
| author | Rouchan Ali Sharma Arvind Virendra Pooja A Chawla |
| author_facet | Rouchan Ali Sharma Arvind Virendra Pooja A Chawla |
| author_sort | Rouchan Ali |
| collection | DOAJ |
| description | Glucagon-like peptide 1 (GLP-1) receptor agonists have acquired importance in Type 2 diabetes (T2D) treatment due to their glycemic advantages, cardiorenal effects, and favorable body weight. Despite this, the continuous discovery of higher effectiveness treatments is critical to addressing ongoing difficulties in the accomplishment of metabolic targets in many T2D patients. Tirzepatide is a unimolecular dual GLP-1 and Glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is being developed for the treatment of T2D. Tirzepatide was approved in May 13, 2022 by the United State Food and Drug Administration (USFDA) with the brand name Mounjaro as the first and the only GLP-1 and GIP receptor agonist to treat T2D. This review outlines essential features of tirzepatide including chemistry, synthesis, pharmacology and mechanism of action of tirzepatide as well as pharmacodynamics, pharmacokinetic and reported clinical trials. |
| first_indexed | 2024-12-10T10:38:55Z |
| format | Article |
| id | doaj.art-b941068dccd94deda25c9554dc5c12c5 |
| institution | Directory Open Access Journal |
| issn | 2772-6320 |
| language | English |
| last_indexed | 2024-12-10T10:38:55Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Health Sciences Review |
| spelling | doaj.art-b941068dccd94deda25c9554dc5c12c52022-12-22T01:52:22ZengElsevierHealth Sciences Review2772-63202022-09-014100032Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonistRouchan Ali0Sharma Arvind Virendra1Pooja A Chawla2Department of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy, Moga 142001, Punjab, IndiaDepartment of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy, Moga 142001, Punjab, IndiaCorresponding author.; Department of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy, Moga 142001, Punjab, IndiaGlucagon-like peptide 1 (GLP-1) receptor agonists have acquired importance in Type 2 diabetes (T2D) treatment due to their glycemic advantages, cardiorenal effects, and favorable body weight. Despite this, the continuous discovery of higher effectiveness treatments is critical to addressing ongoing difficulties in the accomplishment of metabolic targets in many T2D patients. Tirzepatide is a unimolecular dual GLP-1 and Glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is being developed for the treatment of T2D. Tirzepatide was approved in May 13, 2022 by the United State Food and Drug Administration (USFDA) with the brand name Mounjaro as the first and the only GLP-1 and GIP receptor agonist to treat T2D. This review outlines essential features of tirzepatide including chemistry, synthesis, pharmacology and mechanism of action of tirzepatide as well as pharmacodynamics, pharmacokinetic and reported clinical trials.http://www.sciencedirect.com/science/article/pii/S2772632022000216Glucose-dependent insulinotropic polypeptide (GIP)Type 2 diabetesTirzepatideGlucagon-like peptide 1 (GLP-1)Clinical trials |
| spellingShingle | Rouchan Ali Sharma Arvind Virendra Pooja A Chawla Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist Health Sciences Review Glucose-dependent insulinotropic polypeptide (GIP) Type 2 diabetes Tirzepatide Glucagon-like peptide 1 (GLP-1) Clinical trials |
| title | Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist |
| title_full | Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist |
| title_fullStr | Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist |
| title_full_unstemmed | Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist |
| title_short | Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist |
| title_sort | bumps and humps in the success of tirzepatide as the first glp1 and gip receptor agonist |
| topic | Glucose-dependent insulinotropic polypeptide (GIP) Type 2 diabetes Tirzepatide Glucagon-like peptide 1 (GLP-1) Clinical trials |
| url | http://www.sciencedirect.com/science/article/pii/S2772632022000216 |
| work_keys_str_mv | AT rouchanali bumpsandhumpsinthesuccessoftirzepatideasthefirstglp1andgipreceptoragonist AT sharmaarvindvirendra bumpsandhumpsinthesuccessoftirzepatideasthefirstglp1andgipreceptoragonist AT poojaachawla bumpsandhumpsinthesuccessoftirzepatideasthefirstglp1andgipreceptoragonist |